HbA1c: How to Interpret Your Result

What HbA1c Actually Measures

HbA1c, also called glycated hemoglobin or simply A1c, quantifies the fraction of hemoglobin molecules in red blood cells that have bonded irreversibly with glucose through a process called glycation. Because red blood cells live an average of 120 days, the test captures a weighted snapshot of blood glucose control over roughly the preceding 8 to 12 weeks, with more recent weeks contributing more heavily to the final number [1].

The test was standardized internationally through the National Glycohemoglobin Standardization Program (NGSP) and aligned with the Diabetes Control and Complications Trial (DCCT) assay. This standardization is what allows clinicians to compare HbA1c values across laboratories and use fixed cutoffs for diagnosis [2]. Unlike a fasting glucose or oral glucose tolerance test, HbA1c does not require any preparation. You can eat and drink normally beforehand, which makes it one of the most practical screening tools for glycemic status.

The American Diabetes Association (ADA) formally endorsed HbA1c for diabetes diagnosis in 2010, establishing the 6.5% threshold that remains the diagnostic standard today [3]. The Endocrine Society and the American Association of Clinical Endocrinology (AACE) have both incorporated HbA1c into their screening and monitoring guidelines, reinforcing its position as the primary marker for long-term glucose control [4].

The Diagnostic Ranges and What They Mean

An HbA1c below 5.7% falls within the normal range for a healthy adult. Results between 5.7% and 6.4% place a patient in the prediabetes category, a metabolic state where blood sugar runs higher than normal but has not yet crossed the diabetes threshold. At 6.5% or above, repeated on a confirmatory test, the ADA considers the diagnosis of type 2 diabetes established [3].

These cutoffs are not arbitrary. They were derived from population studies linking specific HbA1c levels to the risk of diabetic retinopathy, the eye complication that historically anchored diabetes diagnostic criteria. A 2009 international expert committee convened by the ADA, the European Association for the Study of Diabetes, and the International Diabetes Federation reviewed this evidence and concluded that retinopathy risk rises sharply near the 6.5% mark [5].

The prediabetes range carries real clinical weight. The CDC estimates that 97.6 million American adults (38.0% of the adult population) have prediabetes, and 80% of them do not know it [6]. Progression from prediabetes to type 2 diabetes occurs at a rate of approximately 5% to 10% per year without intervention, but the Diabetes Prevention Program (DPP) trial (N=3,234) showed that structured lifestyle modification reduced conversion by 58% over 2.9 years [7].

The AACE recommends using HbA1c alongside fasting plasma glucose when there is diagnostic uncertainty, particularly in patients with HbA1c values near the 6.5% boundary. As the AACE 2023 consensus statement notes: "No single glycemic measure should be used in isolation; concordance between A1c and glucose-based tests strengthens diagnostic confidence" [4].

Converting HbA1c to Estimated Average Glucose

One of the most practical steps in interpretation is translating your HbA1c percentage into an estimated average glucose (eAG) value. The conversion is based on the A1c-Derived Average Glucose (ADAG) study, a multicenter trial that correlated HbA1c with continuous glucose monitoring data and frequent fingerstick readings in 507 participants across three racial/ethnic groups [8].

The formula is straightforward: eAG (mg/dL) = 28.7 × HbA1c − 46.7. So an HbA1c of 7.0% translates to an eAG of approximately 154 mg/dL. An HbA1c of 6.0% maps to about 126 mg/dL. This linear relationship holds reliably between HbA1c values of 5.0% and 12.0% [8].

Here is a quick reference:

• 5.0% corresponds to an eAG of ~97 mg/dL
• 5.7% corresponds to an eAG of ~117 mg/dL
• 6.5% corresponds to an eAG of ~140 mg/dL
• 7.0% corresponds to an eAG of ~154 mg/dL
• 8.0% corresponds to an eAG of ~183 mg/dL
• 9.0% corresponds to an eAG of ~212 mg/dL
• 10.0% corresponds to an eAG of ~240 mg/dL

This conversion helps patients anchor an abstract percentage to a number they may already recognize from home glucose meters. It also helps explain why two patients with identical fasting glucose readings can have different HbA1c values: HbA1c captures postmeal glucose spikes that a single fasting test misses.

What a High HbA1c Means for Your Health

An HbA1c above 6.5% signals sustained hyperglycemia, and the complications associated with it follow a dose-response pattern. The DCCT (N=1,441) demonstrated that every 1% reduction in HbA1c among people with type 1 diabetes cut the risk of microvascular complications (retinopathy, nephropathy, neuropathy) by approximately 25% to 40% over a mean of 6.5 years [2]. The UK Prospective Diabetes Study (UKPDS, N=5,102), the landmark trial for type 2 diabetes, found a similar gradient: each 1% decrease in HbA1c was associated with a 21% reduction in diabetes-related deaths and a 37% reduction in microvascular endpoints [9].

Cardiovascular risk also rises with HbA1c. A meta-analysis published in the BMJ pooled data from 102 prospective studies (N=698,782) and found that an HbA1c of 6.5% to 6.99% was associated with a hazard ratio of 1.23 for coronary heart disease compared with an HbA1c below 5.0%, after adjustment for conventional risk factors [10]. This graded relationship persisted even in the prediabetes range.

For patients already on glucose-lowering therapy, the ADA's 2024 Standards of Care recommend an HbA1c target of <7.0% for most non-pregnant adults. Tighter targets (<6.5%) may be appropriate for patients with short diabetes duration, long life expectancy, and no significant cardiovascular disease, provided they can achieve it without frequent hypoglycemia. Conversely, a relaxed goal of <8.0% may suit older adults with limited life expectancy, extensive comorbidities, or a history of severe hypoglycemic episodes [11].

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the ADA, has stated: "A1c remains the cornerstone of glycemic management, but it must be interpreted alongside glucose variability, time in range, and the patient's clinical context" [11].

What a Low HbA1c Can Indicate

While most clinical attention focuses on elevated HbA1c, an unusually low result (below 4.0%) also warrants investigation. It does not always mean excellent glucose control.

Low HbA1c can result from conditions that shorten red blood cell lifespan. Hemolytic anemias, sickle cell disease, chronic kidney disease with erythropoietin use, recent blood loss, and recent blood transfusion all reduce the time hemoglobin spends exposed to glucose, pulling the measured HbA1c downward regardless of actual blood sugar levels [12]. Iron deficiency anemia, paradoxically, tends to falsely raise HbA1c because older red blood cells accumulate more glycation.

Pregnancy presents a distinct scenario. Physiologic hemodilution and increased red blood cell turnover in the second and third trimesters lower HbA1c by approximately 0.5%, making it unreliable as a sole monitoring tool for gestational diabetes [13]. The ADA specifically recommends against using HbA1c for diagnosing gestational diabetes and instead relies on the 75 g oral glucose tolerance test [11].

Hypoglycemia from overtreatment is another common cause. An HbA1c of 5.2% in a patient on insulin and a sulfonylurea may mask dangerous glucose lows occurring overnight. Continuous glucose monitoring (CGM) data or structured self-monitoring can reveal the pattern.

Factors That Can Skew Your Result

HbA1c is reliable for most people, but certain biological and clinical situations produce discordant or misleading values.

Hemoglobin variants. Hemoglobin S (sickle cell trait), hemoglobin C, and hemoglobin E can interfere with some HbA1c assay methods, producing falsely high or falsely low results depending on the specific variant and the laboratory's analytical platform. The NGSP maintains a list of assays and their known interferences [14]. If you carry a hemoglobin variant, your clinician should confirm which assay method the lab uses and consider fructosamine or glycated albumin as alternative markers.

Chronic kidney disease. Advanced CKD (stages 4 and 5) alters red blood cell survival and erythropoietin dynamics. HbA1c may underestimate true glycemia in these patients by 0.5% to 1.0% [12].

Iron status. Iron deficiency without anemia can raise HbA1c by 0.3% to 0.6%, while iron supplementation that corrects the deficiency may lower it, independent of any change in blood sugar [15].

Recent transfusion or significant blood loss. Introducing donor red blood cells with different glycation levels or losing a substantial portion of your own cells resets the measurement window. Experts generally recommend waiting 8 to 12 weeks after a major transfusion or hemorrhagic event before relying on an HbA1c result [12].

Certain medications. Dapsone, ribavirin, and antiretrovirals that cause hemolysis can lower HbA1c. High-dose vitamin C (over 500 mg/day in some assays) and chronic opioid use have also been reported to interfere [14].

When clinical suspicion and HbA1c do not match, the ADA recommends using fructosamine (reflecting 2 to 3 weeks of glycemia) or glycated albumin as adjunct measures [11].

How to Lower Your HbA1c

Reducing HbA1c requires sustained improvement in average blood glucose. The strategies fall into three overlapping categories: lifestyle modification, pharmacotherapy, and monitoring.

Diet and physical activity. The DPP trial proved that losing 7% of body weight through a low-calorie, low-fat diet combined with 150 minutes of moderate physical activity per week reduced diabetes incidence by 58% and lowered HbA1c by an average of 0.1% in participants who were already in the prediabetes range [7]. For people with established diabetes, structured exercise programs have been shown to reduce HbA1c by 0.5% to 0.7% in meta-analyses of randomized trials [16].

Metformin remains the first-line pharmacotherapy for most adults with type 2 diabetes, reducing HbA1c by approximately 1.0% to 1.5% at therapeutic doses (1,500 to 2,000 mg/day) [17].

GLP-1 receptor agonists have shown potent HbA1c-lowering effects. In the SUSTAIN-6 trial (N=3,297), semaglutide 1.0 mg once weekly reduced HbA1c by 1.4% from baseline at 104 weeks compared to 0.4% with placebo [18]. Tirzepatide, a dual GIP/GLP-1 receptor agonist, produced HbA1c reductions of up to 2.07% at the 15 mg dose in the SURPASS-1 trial (N=478), with 52% of participants achieving an HbA1c below 5.7% at 40 weeks [19].

SGLT2 inhibitors such as empagliflozin and dapagliflozin typically lower HbA1c by 0.5% to 0.8% and carry additional cardiovascular and renal benefits established in the EMPA-REG OUTCOME and DAPA-CKD trials [20].

Monitoring frequency matters. The ADA recommends checking HbA1c at least twice per year for patients meeting glycemic targets and quarterly for those who are not at goal or whose therapy has recently changed [11]. CGM use has been shown to reduce HbA1c by an additional 0.3% to 0.5% in both type 1 and type 2 diabetes populations, largely by enabling real-time behavioral adjustments [21].

When to Retest and What to Expect

HbA1c reflects a rolling average, so changes in glucose control take time to register. A major medication adjustment or lifestyle change will begin shifting the number within 4 weeks, but the full effect typically takes 8 to 12 weeks to manifest. Retesting too early (before 8 weeks) risks capturing a blended signal that understates your progress.

For screening purposes, the USPSTF recommends that adults aged 35 to 70 who have overweight or obesity be screened for prediabetes and type 2 diabetes every 3 years using HbA1c, fasting plasma glucose, or oral glucose tolerance testing [22]. Adults with prediabetes should be retested annually.

If your HbA1c is discordant with your home glucose readings or CGM data, bring that information to your clinician. The discrepancy itself is clinically meaningful and may point toward one of the interfering conditions described above. Two data sources are always better than one.

Adults with type 2 diabetes whose HbA1c remains above 9.0% despite dual oral therapy should be reassessed for adherence barriers, considered for injectable therapy (GLP-1 agonists or basal insulin), and retested at the 12-week mark per ADA and AACE guidance [4][11].